Mary Brunette, MD
Professor of Psychiatry and Community & Family Medicine and of The Dartmouth Institute; Medical Director, Bureau of Behavioral Health, NH Department of Health & Human Services
Dr. Mary F. Brunette is Professor of Psychiatry and Community & Family Medicine and of The Dartmouth Institute at Dartmouth College and the Medical Director of the Bureau of Behavioral Health within the New Hampshire Department of Health and Human Services. As a board-certified addiction psychiatrist, she has been involved with research and clinical care of patients with severe mental illnesses and co-occurring substance use disorders for over 15 years. She has been active with both psychosocial research and clinical trials studying treatments for people with these co-occurring disorders. In the past few years, she initiated a program of research on smoking cessation for people with severe mental illnesses. With Dr. Joelle Ferron and her research group, she has developed a web-based, motivational decision support system that is tailored for smokers with severe mental illnesses, who typically have cognitive deficits and low computer experience. Several pilot studies indicate that this tool improves engagement in evidence-based treatment. Her future work related to technology will involve using technology to engage people into treatment, improve treatment outcomes, and disseminate evidence-based treatments, with a focus on people with severe mental illnesses in general and nicotine addiction in particular. Dr. Brunette loves to garden, ski, cook and eat great food.
Selected Publications
- Brunette MF, Ferron JC, Devitt T, Geiger P, Martin WM, Pratt S, Santos M, McHugo GJ. Do smoking cessation websites meet the needs of smokers with severe mental illness? Health Education Research. 2012. 27(2) 183-90. PMID:21987478. PMCID: PMC6281343.
- Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011;7(1-2):50-63. doi: 10.1080/15504263.2011.570118. PMID: 25914610; PMCID: PMC4407140.
- Davis K, Brunette MF, Ferron JC, Whitley R. A qualitative study of smoking maintenance and cessation in persons with serious mental illness. Mental Health & Substance Use: Dual Diagnosis. 2010 May 4; 3(2):110-123.
- Brunette MF, Dawson R, O’Keefe C, Buckley P, Green AI. An open label study of quetiapine in patients with schizophrenia and alcohol disorders. Mental Health & Substance Use: Dual Diagnosis. 2009 Sept 18; 2(3):203-11.
- Brunette MF, O’Keefe, C. Zimmet S, Wojcik J, Dawson R, Green AI. Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia. Journal of Dual Diagnosis. 2008 Dec 12; 4:344-354.
- Brunette MF, Asher D, Whitley R, Lutz WJ, Wieder BL, Jones AM, McHugo GJ. Implementation of integrated dual disorders treatment: a qualitative analysis of facilitators and barriers. Psychiatric Services. 2008 Sep;59(9):989-95. doi: 10.1176/appi.ps.59.9.989. PMID: 18757591.
- Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Current Psychiatry Reports. 2005 Aug;7(4):283-91. Review. PMID: 16098282.